ALX Oncology
ALXO
108 hedge funds and large institutions have $780M invested in ALX Oncology in 2021 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 37 increasing their positions, 22 reducing their positions, and 36 closing their positions.
68% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 22
4.07% more ownership
Funds ownership: 85.54% → 89.61% (+4.1%)
5% less funds holding
Funds holding: 114 → 108 (-6)
14% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 36
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
48% less call options, than puts
Call options by funds: $262K | Put options by funds: $503K
69% less capital invested
Capital invested by funds: $2.55B → $780M (-$1.77B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$57.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$25.1M |
| 3 |
Two Sigma Investments
New York
|
+$16.7M |
| 4 |
PC
Pier Capital
Stamford,
Connecticut
|
+$9.74M |
| 5 |
Morgan Stanley
New York
|
+$7.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$41.1M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$31.2M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$17M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$10.8M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$10.8M |
ALXO Hedge Fund Activity: Q4 2021 in Review
108 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q4 2021, worth a combined $780M — down 69% from $2.55B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of ALXO and 31 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 37 added.
The largest buyer was Fidelity Investments, adding an estimated $57.5M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $41.1M sold.
- 108 institutional investors held ALX Oncology (ALXO) as of Q4 2021, down from 114 in Q3 2021.
- Funds reported $780M of ALX Oncology stock for Q4 2021, down 69% quarter-over-quarter.
- 31 funds opened new ALX Oncology positions in Q4 2021 and 36 closed out, a net change of -5 holders.
- The largest ALX Oncology buyer in Q4 2021 was Fidelity Investments, an estimated $57.5M added.
- The largest ALX Oncology seller in Q4 2021 was Lord, Abbett & Co, an estimated $41.1M sold.
Based on aggregated 13F filings for Q4 2021.